Intensive Chemotherapy with and without Cranial Radiation for Burkitt Leukemia and Lymphoma: Final Results of Cancer and Leukemia Group B Study 9251

Cancer

Volumn 100, Issue 7, 2004, Pages 1438-1448

  Rizzieri, David A ^a   Johnson, Jeffrey L ^b   Niedzwiecki, Donna ^b   Lee, Edward J ^c   Vardiman, James W ^d   Powell, Bayard L ^e   Barcos, Maurice ^f   Bloomfield, Clara D ^g   Schiffer, Charles A ^h   Peterson, Bruce A ⁱ   Canellos, George P ^j   Larson, Richard A ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c Maryland Oncology   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

Burkitt leukemia; Burkitt lymphoma; Central nervous system prophylaxis non Hodgkin lymphoma; Chemotherapy; Small noncleaved cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; IFOSFAMIDE; MESNA; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; APHASIA; ARTICLE; BLINDNESS; BONE MARROW SUPPRESSION; BURKITT LEUKEMIA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DELIRIUM; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HUMAN; INFECTION; LETHARGY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MUCOSA INFLAMMATION; MYELITIS; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; SEIZURE; SKIN TOXICITY; SKULL IRRADIATION; STOMATITIS; STUPOR; SURVIVAL RATE; TUMOR LYSIS SYNDROME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LEUKEMIA, B-CELL, ACUTE; MALE; METHOTREXATE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 12144291216     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20143     Document Type: Article

References (27)

1. Simon R, Durrleman S, Hoppe RT, et al. The Non-Hodgkin Lymphoma Classification Project: long-term follow up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med. 1988;109:939-945.
2. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of NHL. Summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
3. Mashal RD, Cannellos GP. Small non-cleaved cell lymphoma in adults. Am J Hematol. 1991;38:40-47.
4. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma/leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:181-184.
5. Patte C, Philip T, Rodary C, et al. High survival rate in advanced stage B-cell lymphomas and leukemias without CNS involvement with a short intensive poly-chemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991;9:123-132.
6. Soussain C, Patte C, Ostronoff M, et al. Small non-cleaved cell leukemia and lymphoma in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85:664-674.
7. Hoelzer D, Ludwig W, Thiel E, et al. Improved outcome in adult B cell acute lymphoblastic leukemia. Blood. 1996;87:495-508.
8. Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small non-cleaved cell lymphoma or FAB L3 lymphocytic leukemia: results of CALGB 9251. J Clin Oncol. 2001;19:4014-4022.
9. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
11. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt lymphoma and B-cell acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986;4:1732-1739.
12. Schwenn MR, Blattner SR, Lynch E, Weinstein HJ. HiCOM: a two-month intensive chemotherapy regimen for children with Stage III and IV Burkitt lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol. 1991;9:133-138.
13. Hann IM, Eden OB, Barnes J, Pinkerton CR. MACHO chemotherapy for Stage IV B-cell lymphoma and B-cell acute lymphoblastic leukemia of childhood. Br J Haematol. 1990;76:359-364.
14. McMaster ML, Greer JP, Greco FA, Hohnson DH, Wolff SN, Hainsworth JD. Effective treatment of small non-cleaved cell lymphoma with high-intensity brief-duration chemotherapy. J Clin Oncol. 1991;9:941-946.
15. Mead MG, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264-1274.
16. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 1995;85:2025-2037.
17. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925-934.
18. Adde M, Shad A, Venzon D, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol. 1998;25(2 Suppl 4):33-39; discussion, 45-48.
19. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992;80:2471-2478.
20. Symonds RP, McIlroy P, Khorrami J, et al. The reduction of radiation oral mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer. 1996;74:312-317.
21. Symonds RP, McIlroy P, Khorrhami J, et al. The reduction of radiation oral mucositis by selective decontamination antibiotic pastilles; a placebo controlled double blind trial. Br J Cancer. 1996;74:312-317.
22. Dorr W, Spekl K, Farrell CL. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif. 2002;35 Suppl 1:86-92.
23. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17:2461-2470.
24. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370-3379.
25. Reiter A, Schrappe M, Tiemann M. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94:3294-3306.
26. Aiello A, Delia D, Fontanella E, et al. Expression of differentiation and adhesion molecules in sporadic Burkitt lymphoma. Hematol Oncol. 1990;8:229-238.
27. Rosanda C, Cantu-Rajnoldi A, Invernizzi R, et al. B-cell acute lymphoblastic leukemia (B-ALL): a report of 17 pediatric cases. Haematologica. 1992;77:151-155.